ARCUS BIOSCIENCES, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.55 USD | +5.57% |
|
+6.58% | -18.59% |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 463.2 | 1,685 | 2,843 | 1,497 | 1,430 | 1,414 | - | - |
| Enterprise Value (EV) 1 | 405.2 | 956.8 | 2,344 | 488.4 | 670.7 | 804.3 | 1,145 | 1,486 |
| P/E ratio | -5.23 x | -11.6 x | 57 x | -5.57 x | -4.6 x | -4.04 x | -3.64 x | -4.27 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 30.9 x | 21.7 x | 7.43 x | 13.4 x | 12.2 x | 7.08 x | 8.62 x | 8.91 x |
| EV / Revenue | 27 x | 12.3 x | 6.12 x | 4.36 x | 5.73 x | 4.02 x | 6.98 x | 9.36 x |
| EV / EBITDA | -4.76 x | -7.9 x | 40.3 x | -1.78 x | -2.02 x | -2.78 x | -2.91 x | -2.94 x |
| EV / FCF | -5.38 x | 8.85 x | -8.3 x | 1.13 x | - | -2.92 x | -3.78 x | -8.49 x |
| FCF Yield | -18.6% | 11.3% | -12% | 88.5% | - | -34.3% | -26.4% | -11.8% |
| Price to Book | - | - | - | 2.29 x | 3.12 x | 3.18 x | -14 x | - |
| Nbr of stocks (in thousands) | 45,859 | 64,923 | 70,249 | 72,408 | 74,856 | 90,953 | - | - |
| Reference price 2 | 10.10 | 25.96 | 40.47 | 20.68 | 19.10 | 15.55 | 15.55 | 15.55 |
| Announcement Date | 3/5/20 | 2/24/21 | 2/23/22 | 2/28/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 15 | 77.52 | 382.9 | 112 | 117 | 199.9 | 164 | 158.7 |
| EBITDA 1 | -85.13 | -121.1 | 58.09 | -274 | -332 | -289 | -393.4 | -505.9 |
| EBIT 1 | -88.71 | -124.2 | 54.25 | -280 | -340 | -337.2 | -416.7 | -381.8 |
| Operating Margin | -591.39% | -160.27% | 14.17% | -250% | -290.6% | -168.73% | -254.06% | -240.54% |
| Earnings before Tax (EBT) 1 | -84.71 | -122.9 | 54.64 | -266 | -301 | -338.1 | -418.5 | -357.2 |
| Net income 1 | -84.71 | -122.9 | 52.83 | -267 | -307 | -324.8 | -381.8 | -348.5 |
| Net margin | -564.73% | -158.49% | 13.8% | -238.39% | -262.39% | -162.54% | -232.82% | -219.56% |
| EPS 2 | -1.930 | -2.240 | 0.7100 | -3.710 | -4.150 | -3.847 | -4.273 | -3.645 |
| Free Cash Flow 1 | -75.39 | 108.1 | -282.2 | 432 | - | -275.5 | -302.5 | -175 |
| FCF margin | -502.58% | 139.47% | -73.72% | 385.71% | - | -137.85% | -184.45% | -110.26% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/5/20 | 2/24/21 | 2/23/22 | 2/28/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 9.461 | 354.5 | 18 | 26.76 | 33.58 | 34 | 25 | 29 | 32 | 31 | 28.77 | 30.06 | 30.2 | 29.49 | 27.36 |
| EBITDA 1 | - | - | - | - | - | -72.52 | - | - | - | -88 | -98.7 | -99.74 | -100.8 | -101.9 | - |
| EBIT 1 | -78.14 | 281.3 | -67.18 | -68.98 | -69.4 | -74 | -86 | -83 | -80 | -91 | -90.94 | -92.35 | -94.69 | -95.55 | -92 |
| Operating Margin | -825.87% | 79.34% | -373.12% | -257.79% | -206.66% | -217.65% | -344% | -286.21% | -250% | -293.55% | -316.04% | -307.21% | -313.52% | -324.02% | -336.26% |
| Earnings before Tax (EBT) 1 | -77.98 | 281.2 | -66.99 | -66.63 | -64.92 | -67 | -78 | -74 | -69 | -80 | -84.62 | -84.87 | -88.22 | -90.72 | -92 |
| Net income 1 | -77.98 | 279.4 | -67.99 | -66.63 | -64.92 | -67 | -80 | -75 | -69 | -81 | -84.82 | -85.07 | -88.42 | -90.92 | -92 |
| Net margin | -824.17% | 78.81% | -377.63% | -249.01% | -193.32% | -197.06% | -320% | -258.62% | -215.62% | -261.29% | -294.78% | -282.99% | -292.77% | -308.31% | -336.26% |
| EPS 2 | -1.110 | 3.710 | -0.9600 | -0.9300 | -0.9000 | -0.9300 | -1.090 | -1.040 | -0.9400 | -1.080 | -0.9717 | -0.9583 | -0.9867 | -1.020 | -1.050 |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/8/21 | 2/23/22 | 5/9/22 | 8/3/22 | 11/2/22 | 2/28/23 | 5/9/23 | 8/7/23 | 11/7/23 | 2/21/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | - | - | - | 71.9 |
| Net Cash position 1 | 57.9 | 729 | 499 | 1,009 | 759 | 610 | 270 | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | -0.142 x |
| Free Cash Flow 1 | -75.4 | 108 | -282 | 432 | - | -276 | -303 | -175 |
| ROE (net income / shareholders' equity) | - | - | 7.86% | -35.6% | -54.9% | -58.1% | -201% | -118% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | - | - | 9.010 | 6.120 | 4.890 | -1.110 | - |
| Cash Flow per Share 2 | - | - | - | 6.080 | -4.140 | 1.500 | -4.750 | - |
| Capex 1 | 1.93 | 3.06 | 26.1 | 6 | - | 31 | 34 | 37.5 |
| Capex / Sales | 12.83% | 3.94% | 6.81% | 5.36% | - | 15.51% | 20.73% | 23.63% |
| Announcement Date | 3/5/20 | 2/24/21 | 2/23/22 | 2/28/23 | 2/21/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
D+
Sell
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
15.55
USD
Average target price
38.89
USD
Spread / Average Target
+150.09%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -18.59% | 1.41B | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- RCUS Stock
- Financials Arcus Biosciences, Inc.
